Oncorus lays off most of its remaining team, including CEO, as it faces bankruptcy or liquidation – Endpoints News
Illumina’s board appointed two new members, including Hologic CEO Stephen MacMillan as non-executive chairman, a move that followed a proxy fight that led to the removal of the company’s chairman by shareholders.
The DNA sequencing company also named Scott Ullem, chief financial officer of Edwards Lifesciences, to its board, according to a company statement.
Illumina’s plans to add two new directors came as Carl Icahn led a proxy campaign that culminated in shareholders electing his candidate, Andrew Teno, over chairman John Thompson. Illumina CEO Francis deSouza survived a threat to the board seat by securing more than twice as many shareholder votes as his challenger. Another Illumina candidate, Robert Epstein, was also elected and remained on the board.
Continue reading Endpoints with a free subscription
Unlock this story immediately and join over 1[ads1]70,400 biopharma professionals who read Endpoints daily—and it’s free.
